Roche personalized cancer treatment Rozlytrek priced at Rs 12 lakh per month Medical Dialogues Bureau17 Aug 2019 9:15 AM ISTRozlytrek was approved by the U.S. Food and Drug Administration on Thursday to treat certain types of solid tumours, which show rare genetic anomalies...
Gilead Sciences new drug keeps 56 percent of lymphoma trial patients alive Ruby Khatun Khatun11 Dec 2017 10:30 AM ISTMore than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a...
This 5 billion dollars startup made its first Cancer vaccine - for just one person Ruby Khatun Khatun18 Nov 2017 10:15 AM ISTBy Caroline ChenFor Moderna Therapeutics, the road to a cancer breakthrough begins on the back of a FedEx truck.Six weeks ago, a 1-millimeter cube of...
Novartis posts a win, Roche a flop in skin cancer trials Ruby Khatun Khatun12 Sept 2017 12:30 PM ISTZURICH/MADRID: Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche...
After melanoma surgery, Bristols Opdivo offers new care standard Ruby Khatun Khatun12 Sept 2017 9:15 AM ISTMADRID: Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients...
Bristol-Myers stops kidney cancer drug test after early success Ruby Khatun Khatun11 Sept 2017 10:48 AM ISTBristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end...
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in Immuno-Oncology Ruby Khatun Khatun9 Sept 2017 9:57 AM ISTKENILWORTH, N.J. & MUNICH: Merck, known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire...
